Vantage logo

The Wegovy wait continues

Novo Nordisk delays the full US launch of its obesity drug again, as Lilly breathes down its neck.

Vantage logo

ADA 2022 – Move over Mounjaro?

Lilly believes it has two promising new molecules for diabetes and obesity. But which to choose – and might toxicity yet scupper one or both?